{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:33:10Z","timestamp":1789205590639,"version":"build-2803163510"},"reference-count":32,"publisher":"Wiley","issue":"s5","license":[{"start":{"date-parts":[[2007,12,7]],"date-time":"2007-12-07T00:00:00Z","timestamp":1196985600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:p><jats:bold>Abstract\u2002<\/jats:bold> Creutzfeldt\u2010Jakob disease (CJD) was first described as a clinical entity in the 1920s, first transmitted experimentally in 1968, and first transmitted iatrogenically in 1972 (corneal transplant). Numerous experimental studies in rodents, sheep and primates have since revealed very low levels of infectivity in blood (about 1\/100\u2003000th the level in brain tissue) that can appear as early as half\u2010way through the incubation period, with 5\u201310 fold higher concentrations in leucocytes than plasma. Transfused blood from individuals incubating the variant form of CJD has transmitted infection to four recipients in the United Kingdom, and several dozen other recipients remain at risk. Plasma and plasma proteins have not been implicated in any transmissions, and no instance of transmission from the blood of individuals incubating other forms of CJD has been recognized. Strategies to prevent iatrogenic transmissions include low\u2010risk sourcing, leucodepletion, and a variety of infectivity\u2010reducing plasma processing steps; screening tests to detect infection in preclinical donors are under development.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2007.01572.x","type":"journal-article","created":{"date-parts":[[2010,9,15]],"date-time":"2010-09-15T13:20:54Z","timestamp":1284556854000},"page":"33-40","source":"Crossref","is-referenced-by-count":35,"title":["Creutzfeldt\u2010Jakob disease: reflections on the risk from blood product therapy"],"prefix":"10.1111","volume":"13","author":[{"given":"P.","family":"BROWN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,12,7]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"95","volume-title":"Creutzfeldt\u2010Jakob Disease: Managing the Risk of Transmission by Blood, Plasma, and Tissues","author":"Brown P","year":"2006"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1998.38998408999.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00865.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00098.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.41.1.154-161.1983"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39111169.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0041-1132.2003.00586.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.9.4649-4650.2002"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15486-X"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16811-6"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69835-8"},{"key":"e_1_2_5_13_2","volume-title":"Health Protection Report","author":"Health Protection Agency"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1580"},{"key":"e_1_2_5_15_2","volume-title":"A Novel Immunoassay for the Detection of Resistant Prion Protein (PrPres) in Human Plasma","author":"Perron H"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01284.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91148-7"},{"key":"e_1_2_5_18_2","volume-title":"An update on the Creutzfeldt\u2010Jakob disease look\u2010back study","author":"Zou S"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00833.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)09468-3"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7252.17"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.00640.x"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69897-8"},{"issue":"2","key":"e_1_2_5_24_2","first-page":"8","article-title":"Removal of TSE agents from blood products","volume":"87","author":"Foster PR","year":"2004","journal-title":"Vox Sang"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2003.08.004"},{"key":"e_1_2_5_26_2","first-page":"S45","article-title":"Evaluation de l\u2019effiacit\u00e9 des proc\u00e9d\u00e9s de purification des prot\u00e9ines plasmatiques \u00e0\u00e9liminer les agents transmissibles non conventionnels","volume":"9","author":"Flan B","year":"2005","journal-title":"Virologie"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2005.00683.x"},{"key":"e_1_2_5_28_2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/(SICI)1096-8652(199812)59:4<288::AID-AJH4>3.0.CO;2-I","article-title":"The occurrence of hemophilia in the United States","volume":"59","author":"Souci JM","year":"1998","journal-title":"Am J Hematol"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1998.38998409000.x"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.14.8904-8908.2005"},{"key":"e_1_2_5_31_2","unstructured":"FDA TSEAC Meeting 2006.Topic I: FDA\u2019s risk assessment for variant Creutzfeldt\u2010Jakob disease (vCJD) potentially associated with the use of US licensed human plasma\u2010derived Factor VIII (pdFVIII Anti\u2010Hemophilic Factor) products and potential public health service responses. Available as PDF file at the following FDA website:http:\/\/google2.fda.gov\/search?output=xml_no_dtd&oe=&lr=&proxystylesheet=FDA&client=FDA&site=FDA&getfields=*&q=variant+CJD+risk+assessment&as=Searchusda."},{"key":"e_1_2_5_32_2","first-page":"119","volume-title":"Creutzfeldt\u2010Jakob Disease: Managing the Risk of Transmission by Blood, Plasma, and Tissues","author":"Minor P","year":"2006"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129051"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2007.01572.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2007.01572.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T07:18:55Z","timestamp":1695712735000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2007.01572.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":32,"journal-issue":{"issue":"s5","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1111\/j.1365-2516.2007.01572.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2007.01572.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}